NAD+ depletion as a damage-setting checkpoint that reprograms cellular fate via AMPK‑HIF‑1α crosstalk

Hypothesis

NAD+ decline does not merely reflect damage; it actively initiates a metabolic checkpoint that shifts cells from a proliferative, SASP‑prone state to a quiescent, antifibrotic phenotype through coordinated AMPK activation and HIF‑1α stabilization.

Mechanistic Basis

Accumulated DNA damage hyperactivates PARP1, consuming NAD+ and lowering the NAD+/NADH ratio. This redox shift activates AMPK, which phosphorylates and stabilizes HIF‑1α even under normoxia. AMPK‑HIF‑1α signaling then upregulates genes that enforce cell‑cycle arrest (p21, p27) and downregulate NF‑κB‑driven SASP components, while simultaneously inducing expression of antifibrotic factors such as PPARγ. In parallel, low NAD+ reduces SIRT1 activity, decreasing deacetylation of NF‑κB and further limiting inflammatory transcription. Thus NAD+ depletion functions as a sensor that couples damage signals to a protective transcriptional program, explaining why senescent cells provoke CD38‑mediated NAD+ loss in neighbors yet the resulting low‑NAD+ milieu curtails their own secretory output.

Testable Predictions

1. In tissues where NAD+ falls with age, phospho‑AMPK and HIF‑1α levels will rise concomitantly, and this correlation will be stronger than the correlation between NAD+ levels and chronological age.
2. Pharmacological activation of AMPK (e.g., AICAR) in young, NAD+‑replete cells will mimic the antifibrotic, low‑SASP phenotype seen in aged, NAD+‑low cells, whereas HIF‑1α knock‑down will abolish this effect despite AMPK activation.
3. Senescent‑cell‑conditioned media will increase CD38 expression and NAD+ consumption in naïve fibroblasts, but adding an AMPK inhibitor will prevent the subsequent reduction in SASP factor secretion.
4. NAD+ precursor supplementation will temporarily raise NAD+ levels, blunt AMPK/HIF‑1α signaling, and consequently increase SASP expression in senescent cells, leading to heightened inflammatory markers unless PARP1 is concurrently inhibited.

Experimental Design

• Use murine liver and kidney samples from young (3 mo) and old (24 mo) mice. Measure NAD+, phospho‑AMPK (Thr172), HIF‑1α protein, p21, SASP cytokines (IL‑6, IL‑1β), and fibrosis markers (collagen I, α‑SMA) by western blot and ELISA. Perform linear regression to test prediction 1.
• Treat primary human fibroblasts with AICAR (0.5 mM) for 24 h, with or without HIF‑1α siRNA. Assess SASP secretion and fibrosis‑related gene expression. Test prediction 2.
• Expose naïve fibroblasts to media from irradiated senescent fibroblasts (± CD38 blocking antibody). Add AMPK inhibitor (Compound C) or vehicle. Measure NAD+ levels, SASP output, and fibroblast activation. Test prediction 3.
• Supplement aged mice with NR (400 mg/kg/day) for 4 weeks, with a subgroup receiving PARP1 inhibitor (Olaparib). Evaluate NAD+, AMPK/HIF‑1α activity, SASP, and fibrosis. Test prediction 4.

If predictions 1‑4 hold, NAD+ depletion is positioned as an active, damage‑responsive checkpoint that reallocates cellular resources away from proliferation and inflammation toward a protective, antifibrotic state. Failure to observe the predicted AMPK‑HIF‑1α coupling or the conditional effects of SASP modulation would falsify the hypothesis and support the view that NAD+ loss is merely a passive byproduct of damage.